Is ELDN or AVTX more profitable?

Avalo Therapeutics' return on equity of -97.54% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Avalo Therapeutics N/A -97.54% -72.42%

Does the media refer more to ELDN or AVTX?

In the previous week, Avalo Therapeutics had 2 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Avalo Therapeutics and 5 mentions for Eledon Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 1.17 beat Eledon Pharmaceuticals' score of 0.90 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ELDN or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is ELDN or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media prefer ELDN or OLMA?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat Olema Pharmaceuticals' score of 0.66 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ELDN or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is ELDN or LBRX more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% LB Pharmaceuticals N/A N/A N/A

Does the media favor ELDN or LBRX?

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 9 mentions for LB Pharmaceuticals and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat LB Pharmaceuticals' score of 0.74 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELDN or BIOA?

In the previous week, BioAge Labs had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 12 mentions for BioAge Labs and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat BioAge Labs' score of 0.35 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Eledon Pharmaceuticals (ELDN) Competitors

$3.43 +0.05 (+1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$3.46 +0.02 (+0.73%)

As of 07:34 PM Eastern

Compare

ELDN vs. CVAC, AVTX, OLMA, LBRX, and BIOA

Should you buy Eledon Pharmaceuticals stock or one of its competitors? MarketBeat compares Eledon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eledon Pharmaceuticals include CureVac (CVAC), Avalo Therapeutics (AVTX), Olema Pharmaceuticals (OLMA), LB Pharmaceuticals (LBRX), and BioAge Labs (BIOA).

How does Eledon Pharmaceuticals compare to CureVac?

Eledon Pharmaceuticals (NASDAQ:ELDN) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Eledon Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Eledon Pharmaceuticals presently has a consensus price target of $9.67, indicating a potential upside of 181.83%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has a net margin of 199.92% compared to Eledon Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of -23.03% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
CureVac	199.92%	-23.03%	-19.09%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CureVac has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Eledon Pharmaceuticals had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 0 mentions for CureVac. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat CureVac's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Positive
CureVac	Neutral

Summary

CureVac beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Avalo Therapeutics?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Eledon Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Avalo Therapeutics' return on equity of -97.54% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Eledon Pharmaceuticals has higher earnings, but lower revenue than Avalo Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Avalo Therapeutics	$60K	15,914.08	-$78.26M	-$5.46	N/A

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 181.83%. Avalo Therapeutics has a consensus price target of $45.80, suggesting a potential upside of 153.74%. Given Eledon Pharmaceuticals' higher probable upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Avalo Therapeutics had 2 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Avalo Therapeutics and 5 mentions for Eledon Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 1.17 beat Eledon Pharmaceuticals' score of 0.90 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalo Therapeutics beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 181.83%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 290.96%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals' return on equity of -46.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Eledon Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat Olema Pharmaceuticals' score of 0.66 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

Olema Pharmaceuticals beats Eledon Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to LB Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Eledon Pharmaceuticals presently has a consensus price target of $9.67, suggesting a potential upside of 181.83%. LB Pharmaceuticals has a consensus price target of $45.13, suggesting a potential upside of 5.33%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

LB Pharmaceuticals' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
LB Pharmaceuticals	N/A	N/A	N/A

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, LB Pharmaceuticals had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 9 mentions for LB Pharmaceuticals and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat LB Pharmaceuticals' score of 0.74 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LB Pharmaceuticals beats Eledon Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to BioAge Labs?

Eledon Pharmaceuticals (NASDAQ:ELDN) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eledon Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
BioAge Labs	-871.75%	-29.40%	-27.26%

Eledon Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

In the previous week, BioAge Labs had 7 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 12 mentions for BioAge Labs and 5 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat BioAge Labs' score of 0.35 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 181.83%. BioAge Labs has a consensus target price of $36.57, suggesting a potential upside of 239.25%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Eledon Pharmaceuticals has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
BioAge Labs	$8.99M	53.30	-$80.61M	-$2.40	N/A

Summary

BioAge Labs beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$260.89M	$3.51B	$6.81B	$12.68B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.45	7.32	281.02	25.13
Price / Sales	N/A	1,280.67	590.80	93.66
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.54	16.89	11.02	6.21
Net Income	-$45.62M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-3.92%	-0.63%	0.56%	0.89%
1 Month Performance	-13.16%	-7.41%	-4.14%	-3.60%
1 Year Performance	1.48%	49.17%	63.23%	20.46%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	2.8297 of 5 stars	$3.43 +1.5%	$9.67 +181.8%	+0.0%	$260.89M	N/A	N/A	10
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
AVTX Avalo Therapeutics	3.1726 of 5 stars	$19.52 +0.1%	$45.80 +134.6%	+131.3%	$1.03B	$59K	N/A	40	News Coverage Positive News Upcoming Earnings
OLMA Olema Pharmaceuticals	2.1588 of 5 stars	$11.62 -3.2%	$44.10 +279.5%	+114.8%	$1.01B	N/A	N/A	70	News Coverage Positive News Upcoming Earnings
LBRX LB Pharmaceuticals	1.51 of 5 stars	$34.94 +0.5%	$40.43 +15.7%	N/A	$1.00B	N/A	N/A	16	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CVAC, AVTX, OLMA, LBRX, and BIOA

How does Eledon Pharmaceuticals compare to CureVac?

Summary

How does Eledon Pharmaceuticals compare to Avalo Therapeutics?

Summary

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CVAC, AVTX, OLMA, LBRX, and BIOA

How does Eledon Pharmaceuticals compare to CureVac?

Which has more risk and volatility, ELDN or CVAC?

Do analysts rate ELDN or CVAC?

Is ELDN or CVAC more profitable?

Do insiders and institutionals hold more shares of ELDN or CVAC?

Which has higher valuation and earnings, ELDN or CVAC?

Does the media refer more to ELDN or CVAC?

Summary

How does Eledon Pharmaceuticals compare to Avalo Therapeutics?

Which has more risk & volatility, ELDN or AVTX?

Is ELDN or AVTX more profitable?

Which has stronger valuation and earnings, ELDN or AVTX?

Do analysts rate ELDN or AVTX?

Do insiders & institutionals have more ownership in ELDN or AVTX?

Does the media refer more to ELDN or AVTX?

Summary

How does Eledon Pharmaceuticals compare to Olema Pharmaceuticals?

Do institutionals & insiders have more ownership in ELDN or OLMA?

Do analysts recommend ELDN or OLMA?

Is ELDN or OLMA more profitable?

Which has more volatility and risk, ELDN or OLMA?

Does the media prefer ELDN or OLMA?

Which has higher valuation & earnings, ELDN or OLMA?

Summary

How does Eledon Pharmaceuticals compare to LB Pharmaceuticals?

Which has higher valuation and earnings, ELDN or LBRX?

Do analysts rate ELDN or LBRX?

Is ELDN or LBRX more profitable?

Do insiders & institutionals hold more shares of ELDN or LBRX?

Does the media favor ELDN or LBRX?

Summary

How does Eledon Pharmaceuticals compare to BioAge Labs?

Do institutionals and insiders hold more shares of ELDN or BIOA?

Is ELDN or BIOA more profitable?

Which has more volatility & risk, ELDN or BIOA?

Does the media prefer ELDN or BIOA?

Do analysts recommend ELDN or BIOA?

Which has better earnings and valuation, ELDN or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools